ABSTRACT
Introduction: Seabuckthorn (SBT) has received worldwide attention for therapeutic, nutraceutical and cosmetic purposes. It is used for the treatment of a number of diseases. Hundreds of commercial products containing SBT are available in the market.
Areas covered: This review article covers patents on the therapeutic potential of SBT and its chemical constituents. The therapeutic areas covered in this review include cancer, cardiovascular, diabetes, inflammation, anti-oxidant, and anti-microbial. The patents were searched through Sci-finder, Espacenet, Google Patent, and US Patent.
Expert opinion: Plant-based drugs have played an important role in the modern drug industry. Since ancient times, SBT has been used to cure several ailments. SBT has emerged as an important plant, which has been investigated for numerous pharmacological properties and shown to be beneficial in a number of therapeutic areas. Several clinical trials have demonstrated the therapeutic potential of SBT for the treatment of many diseases including cardiovascular, inflammation, diabetes, platelet inhibition, etc. There is huge potential for developing standardized herbal products from different parts of SBT.
Article highlights
Patents granted on the therapeutic potential of seabuckthorn during 2000 to 2018 are reviewed.
Several formulations have been prepared and evaluated for pharmacological activities.
SBT berries, fruit oil, seed oil and leaf extracts have shown beneficial health effects.
Patents on cancer, cardiovascular diseases, diabetes, inflammation, immunomodulation, ulcer, anti-oxidant and anti-microbial activity are reviewed.
Several clinical trials have shown effective use of SBT in the aforementioned areas.
This box summarizes key points contained in the article.
Acknowledgments
Authors are thankful to Director of NIPER for support.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Correction Statement
This article has been republished with minor changes. These changes do not impact the academic content of the article.